In summary, our study provides evidence that SIRT6 activation is an effective therapeutic strategy for CRC and that this highly characterized SIRT6 activator represents a valuable lead compound for advancing the understanding of the role of SIRT6 as a target in CRC and developing broad therapeutic agents against CRC. This evidence concerns the gene SIRT6 and colorectal carcinoma.